Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

BACKGROUND: The PREFER study was an assessment of medication tolerability, treatment preference and symptom improvement during treatment with mirabegron (M) and tolterodine (T) extended release (ER) in patients with overactive bladder (OAB). In this analysis of PREFER, patient-reported outcomes (PRO...

Descripción completa

Detalles Bibliográficos
Autores principales: Herschorn, Sender, Staskin, David, Tu, Le Mai, Fialkov, Jonathan, Walsh, Terry, Gooch, Katherine, Schermer, Carol R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909214/
https://www.ncbi.nlm.nih.gov/pubmed/29673355
http://dx.doi.org/10.1186/s12955-018-0892-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909214/
https://www.ncbi.nlm.nih.gov/pubmed/29673355
http://dx.doi.org/10.1186/s12955-018-0892-0

Ejemplares similares